Outcomes associated with antidepressant treatment according to the number of prescriptions and treatment changes: 5-year follow-up of a nation-wide cohort study.

Background: Naturalistic studies regarding clinical outcomes associated with antidepressant treatment duration have yielded conflicting results, possibly because they did not consider the occurrence of treatment changes. This nation-wide population-based study examined the association between the number of filled prescriptions and treatment changes and long-term psychiatric outcomes after antidepressant treatment initiation.

Methods: Based on the French national health insurance database, 842,175 adults who initiated an antidepressant treatment in 2011 were included.

What is the care pathway of patients who undergo thyroid surgery in France and its potential pitfalls? A national cohort.

Context: The rate of thyroid cancer is increasing in France, as well as concerns about overdiagnosis and treatment.

Objectives: To examine the care pathway of patients who undergo thyroid surgery in France and detect potential pitfalls.

Design: A large observational study based on medical reimbursements, 2009-2011.

[The human and economic burden of cancer in France in 2014, based on the Sniiram national database].

Introduction: The national health insurance information system (Sniiram) can be used to estimate the national medical and economic burden of cancer. This study reports the annual rates, characteristics and expenditure of people reimbursed for cancer.

Methods: Among 57 million general health scheme beneficiaries (86% of the French population), people managed for cancer were identified using algorithms based on hospital diagnoses and full refund for long-term cancer.

[Management of patients with end-stage renal disease prior to initiation of renal replacement therapy in 2013 in France].

This study evaluated the management of patients with end-stage renal disease prior to initiation of renal replacement therapy. Among the 51 million national health insurance general scheme beneficiaries (77% of the population), persons 18 years and older, starting dialysis or undergoing preemptive renal transplantation in 2013, were included in this study. Data were derived from the French national health insurance system (SNIIRAM).

Two-year outcome of patients after a first hospitalization for heart failure: A national observational study.

Background: National population-based management and outcome data for patients of all ages hospitalized for heart failure have rarely been reported.

Aim: National population-based management and outcome of patients of all ages hospitalized for heart failure have rarely been reported. The present study reports these results, based on 77% of the French population, for patients hospitalized for the first time for heart failure in 2009.

Isotretinoin and risk of inflammatory bowel disease: a French nationwide study.

Objectives: Isotretinoin, a drug widely prescribed for severe acne, has been suspected to increase the risk of ulcerative colitis (UC), but data are conflicting. To further examine the association between isotretinoin use and risk for UC and Crohn's disease (CD), we conducted a large nationwide case-control study in France.

Methods: We used information from the National Health Insurance system for all French people covered by the general scheme between 1 January 2008 and 31 December 2010, totaling over 50 million individuals (i.

First hospitalization for heart failure in France in 2009: patient characteristics and 30-day follow-up.

Background: The incidence of heart failure (HF) is stable in industrialized countries, but its prevalence continues to increase, especially due to the ageing of the population, and mortality remains high.

Objective: To estimate the incidence in France and describe the management and short-term outcome of patients hospitalized for HF for the first time.

Method: The study population comprised French national health insurance general scheme beneficiaries (77% of the French population) hospitalized in 2009 with a principal diagnosis of HF after exclusion of those hospitalized for HF between 2006 and 2008 or with a chronic disease status for HF.